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ABSTRACT Guidelines recommend the use of an algorithm for the laboratory diag-
nosis of Clostridium difﬁcile infection (CDI). Enzyme immunoassays (EIAs) detecting C.
difﬁcile toxins cannot be used as standalone tests due to suboptimal sensitivity, and
molecular tests suffer from nonspeciﬁcity by detecting colonization. Sensitive immu-
noassays have recently been developed to improve and simplify CDI diagnosis. As-
says detecting CD toxins have been developed using single-molecule array (SIMOA)
technology. SIMOA performance was assessed relative to a laboratory case deﬁnition
of CDI deﬁned by positive glutamate dehydrogenase (GDH) screen and cell cytotox-
icity neutralizing assay (CCNA). Samples were tested with SIMOA assays and a com-
mercial toxin EIA to compare performance, with discrepancy resolution using a com-
mercial nucleic acid-based test and a second cell cytotoxicity assay. The SIMOA toxin
A and toxin B assays showed limits of detection of 0.6 and 2.9 pg/ml, respectively,
and intra-assay coefﬁcients of variation of less than 10%. The optimal clinical thresh-
olds for the toxin A and toxin B assays were determined to be 22.1 and 18.8 pg/ml,
respectively, with resultant sensitivities of 84.8 and 95.5%. In contrast, a high-
performing EIA toxin test had a sensitivity of 71.2%. Thus, the SIMOA assays de-
tected toxins in 24% more samples with laboratory-deﬁned CDI than the high per-
forming toxin EIA (95% [63/66] versus 71% [47/66]). This study shows that SIMOA C.
difﬁcile toxin assays have a higher sensitivity than currently available toxin EIA and
have the potential to improve CDI diagnosis.
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Clostridium difﬁcile infection (CDI) is a gastrointestinal disease caused by the Gram-positive bacteria Clostridium difﬁcile (CD). This pathogen is responsible for pseu-
domembranous colitis and almost a quarter of all antibiotic-associated diarrhea (1). CDI
has been shown to be common, serious, and costly (2), with varied disease severity that
is associated with strain virulence and patient risk factors (3–6).
Guidelines exist that provide recommendations on how to diagnose and treat CDI
patients (7–10). Accurate diagnosis is essential to control endemic spread and out-
breaks and to provide appropriate treatment to the patient (11). Diagnostic tests detect
the bacteria, bacterial components such as glutamate dehydrogenase (GDH), the toxins
responsible for the disease, or genetic components such as the toxin genes. The
presence of C. difﬁcile toxins in a diarrheal fecal specimen may be the most reliable
indicator of true CDI (12). However, toxin testing by current enzyme immunoassays
(EIAs) is not suitable as a standalone test due to their lack of sensitivity. There are
several commercially available EIAs for toxin detection, but none of them are as
sensitive as the gold-standard method, the cell cytotoxicity neutralizing assay (CCNA),
which measures toxin B cytotoxic activity (13, 14). Nevertheless, most laboratories do
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not perform the CCNA, as it is time consuming, requires cell-culture facilities and
advanced technical skills, and has never been standardized. For these reasons, guide-
lines strongly recommend a two-stage testing approach (8, 10). This approach consists
of the use of a highly sensitive assay with a high negative predictive value (thus ruling
out CDI with a negative result), followed by secondary testing of positive specimens
with an assay for the detection of C. difﬁcile toxins. The highly sensitive assay recom-
mended as a ﬁrst step is either an EIA detecting GDH or a molecular assay detecting
toxin genes. A positive result with molecular assay, if used as the only test for CDI, must
be interpreted with caution, as it may be detecting carriage or colonization by a
toxigenic strain in individuals who have diarrhea for other reasons (15). This is an
important point to highlight, especially as the carriage rate can sometimes be quite
high, up to 15% in adults (16, 17).
An automated one-step assay capable of detecting very small amounts of C. difﬁcile
toxins in a fecal sample could provide a signiﬁcant improvement in the diagnosis of
CDI. It has previously been shown that the single-molecule array (SIMOA) technology is
able to detect a very low quantity of analyte in biological samples (18, 19). The
development of sensitive assays by SIMOA for the detection of C. difﬁcile A and B toxins
in stool has shown promising results in comparison to toxigenic culture, CCNA, and
molecular assay (20, 21). The objective of this study was to show that SIMOA toxin A
and toxin B assays have a better analytical performance in comparison with one of the
optimal EIAs currently available (13, 14).
MATERIALS AND METHODS
Clinical stool samples. Frozen stool samples from Canadian (Jewish General Hospital, Montreal,
Canada) and French (Charcot private hospital, Sainte-Foy-lès-Lyon, France) hospitals were used to
determine the limit of detection (LOD) and the reproducibility of the two SIMOA toxin assays. For
sensitivity and speciﬁcity studies, clinical samples (n  240) were collected at the Leeds Teaching
Hospitals NHS Trust in 2014 (Leeds, United Kingdom), and kept at 80°C. These samples were charac-
terized for CDI status using a laboratory case deﬁnition deﬁned by positive GDH screen and CCNA toxin
assay. Informed consent was not required for the use of anonymized residual diagnostic material, and
appropriate ethical approval was granted for use of the samples from Leeds by the University of Leeds.
Sample preparation for SIMOA assays. Frozen stool samples were thawed, then homogenized
using a plastic spatula, and 50 to 100 mg of sample were transferred into an Eppendorf tube. The exact
quantity of stool was determined by weighing the tube, and the volume of sample diluent added was
adjusted to achieve a ﬁnal dilution of 1/21 (mg/ml). Sample diluent consisted in Tris-buffered saline (pH
7.4) containing detergent and preservative. The tube contents were mixed using a vortex and centri-
fuged at 3,000  g for 10 min. The supernatant was collected and tested for toxins.
SIMOA toxin assays. The SIMOA toxin A and toxin B assays were manufactured with the same raw
materials as those previously described (20, 21), except for calibrators, antitoxin A antibodies (Ab), and
detector. We used native toxins A and B, puriﬁed from C. difﬁcile strain VPI 10463, toxinotype 0 (Native
Antigen Company, Oxfordshire, United Kingdom), as calibrators; anti-toxin A antibodies from bioMérieux
(bioMérieux, Marcy l’Etoile, France); and detector antibody directly conjugated to the enzyme
-galactosidase (Roche Diagnostics Corporation, Indianapolis, IN). Both toxin A and toxin B assays were
composed of paramagnetic beads (Quanterix Corporation, Lexington, MA) coated with Ab directed
against toxin A or B and detectors speciﬁc for each toxin. Assays were performed on a SIMOA HD-1
Analyzer (Quanterix Corporation, Lexington, MA) located at bioMérieux in France. Supernatants of
specimens were tested in duplicate in each SIMOA run along with calibrators and controls. The controls
were positive and negative stool samples characterized by French hospitals.
Limits of detection (LOD) and limits of quantiﬁcation (LOQ), repeatability, and reproducibility
of SIMOA assays. Six runs were performed, one run per day, for six days. Each run was composed of
eight calibrators in duplicate, two negative samples, and 20 positive stool samples in quadruplet. The
limit of blank (LOB) was determined as the 95th percentile of the blank sample distribution and
calculated nonparametrically on 60 values (two negative samples tested in quadruplet and one sample
diluent tested in duplicate per run on six runs). LOD and LOQ of the assays were determined by using
the precision proﬁle method on the six lowest positive samples. The precision proﬁle characterizes the
relationship between the standard deviation (SD) and the toxin concentrations. The mathematical model
is a second-order polynomial equation: SD  a0  a1X  a2X2 with a0, a1, and a2 corresponding to the
parameters estimated for the second-order model and X being the concentration at the LOD level. LOD
was calculated as LOD  LOB  Cp · SD, where Cp is a corrector factor of the SD, taking into account
the total number of samples (Ntot) and the number of replicates per sample (K),
Cp
1.645
1  14(Ntotal K)
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The value of 1.645 represents the 95th percentile from the normal distribution for a risk, , equal to
0.05. LOQ was deﬁned as minimal concentration for a 10% coefﬁcient of variation (CV) and calculated by
resolution of the equation 0.1 LOQ  a0  a1LOQ  a2 · LOQ2, with SD  CV · LOQ. LOB, LOD, and LOQ
are expressed in pg/ml in pretreated samples (not corrected by dilution factor applied during stool
pretreatment). The repeatability and reproducibility study was assessed using the SAS-Add-In 4.3
software (SAS Institute, Cary, NC) on 20 samples (24 values per sample).
Repeatability of sample preparation for toxin detection. Eighteen frozen clinical samples of
different consistencies were selected, consisting of six liquid samples (Bristol stool chart type 7), six
semiformed samples (Bristol stool chart types 5 and 6), and six formed stool samples (Bristol stool chart
types 1 to 4). Samples were ﬁrst homogenized with a plastic spatula. Eight individual sample preparations
were then performed for each sample and tested in triplicate with the SIMOA toxin A assay to determine
the variability in toxin concentration obtained between sample preparations. Due to the number of
sample preparations done for each specimen, toxin quantiﬁcation on freshly prepared samples was done
with the SIMOA toxin A assay only. As the aim of this study was to evaluate the repeatability of sample
preparation, we selected the SIMOA assay with the best repeatability to reduce/limit the variability due
to the SIMOA assay and instrument.
Clinical sensitivity and speciﬁcity of SIMOA toxin assays. The clinical threshold of the SIMOA
assays was determined with a ROC (receiver operating characteristics) curve. This curve was drawn with
Analyse-it software (Analyse-it Software, Ltd., Leeds, United Kingdom) using the concentration obtained
for each diluted sample and the patient’s CDI status, as determined by laboratory case deﬁnition. The
clinical thresholds were chosen according to the Youden’s index value given by the software. The
sensitivity and speciﬁcity obtained for SIMOA assays using the selected clinical thresholds were deter-
mined by comparison to the laboratory case deﬁnition. A patient was diagnosed with CDI if the fecal
sample was found positive by GDH and CCNA assays, while a patient was considered CDI negative if the
sample was found to be negative by GDH or CCNA assay. The sensitivity and speciﬁcity are given as
percentages with the 95% conﬁdence interval (95% CI) values.
Comparison to a commercially available immunoassay. All samples were tested with the com-
mercially available C. difﬁcile Tox A/B II assay (Techlab, Blacksburg, VA), a fecal C. difﬁcile toxin A and toxin
B enzyme immunoassay, according to the manufacturer’s instructions. The C. difﬁcile Tox A/B II assay was
performed in parallel with the SIMOA assay, using the same aliquot. One-third of the samples had an
additional freezing/thawing cycle before testing with the C. difﬁcile Tox A/B II assay.
Toxin gene detection by molecular assay. The Xpert C. difﬁcile assay (Cepheid Inc., Sunnyvale, CA)
was performed using the Cepheid GeneXpert Systems. Sixty of the 96 GDH-positive CCNA-negative
samples were tested with the Xpert C. difﬁcile assay by the Leeds laboratory as part of an internal
evaluation. At bioMérieux, the testing of the 36 GDH-positive CCNA-negative samples was completed, as
well as additional testing for samples that gave discordant results between CCNA and the SIMOA assay.
Cell cytotoxicity neutralizing assay (CCNA). CCNA was performed at bioMérieux (bMx CCNA), on
fecal samples that showed discordant results between the CCNA obtained by the Leeds laboratory and
SIMOA, to verify that the toxin was present and functional in the samples. Vero cells (ATCC CCL-81) were
inoculated at 30,000 cells/well on the day prior to the test. Samples were solubilized in minimum
essential medium (MEM) with 1% fetal calf serum and 1% gentamicin, streptomycin, penicillin, and
amphotericin B (Thermo Fisher Scientiﬁc, Waltham, MA) at 1/6 dilution and centrifuged at 3,000  g for
10 min. The supernatant was then diluted 1/10 and ﬁltered at 0.45 m, and three other successive
dilutions were done to achieve the following ﬁnal dilutions: 1/120; 1/1 200; 1/12,000; and 1/120,000.
Positive and negative controls (stool samples and media) were tested in parallel to the samples. A
neutralizing antitoxin B Ab (Meridian Life Science, Memphis, TN) was used to verify that the cytotoxic
activity was caused by toxin B. The plate was examined at 24 and 48 h for cell rounding. In terms of
analytical sensitivity of the bMx CCNA assay, we have observed high cytotoxic activity using native toxin
A at 250 pg/ml, moderate activity at 100 pg/ml, low activity at 20 pg/ml, and no activity at 10 pg/ml. For
native puriﬁed toxin B the cytotoxic activity was high at 5 pg/ml, moderate at 1.5 pg/ml, low at 0.2 pg/ml,
and nonexistent at 0.02 pg/ml.
The differences with the method used at the Leeds Hospital (Leeds CCNA) were the following: the
origin of Vero cells (European Collection of Authenticated Cell Cultures, Wiltshire, United Kingdom), the
diluent used to dilute the stool sample (phosphate-buffered saline), the preparation of the sample
(ﬁltration of sample supernatant), the anti-toxin antibody (C. sordelli antitoxin, Prolab, United Kingdom),
and the tested dilutions (1/100 and 1/1,000).
RESULTS
Limits of detection and quantiﬁcation, repeatability, and reproducibility of
SIMOA assays. The toxin A and toxin B concentrations in diluted fecal specimen were
determined using calibration curves ranging from 1 to 2,000 pg/ml (Fig. 1). The LOBs
obtained with the negative samples were 0.4 and 2.4 pg/ml for toxins A and B,
respectively, while the LODs of SIMOA toxin A and toxin B assays were 0.6 and 2.9
pg/ml (Table 1), respectively. LOQ equaled LOD for the toxin B assay, as CVs of samples
in this concentration range were below 10%. Intra-assay and interassay CVs for samples
above the LOQ were below 10% for the SIMOA assays, except for 1 sample having an
interassay CV of 10.4% for the SIMOA toxin A assay and 2 samples having interassay CVs
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of 11.3% and 14% for the SIMOA toxin B assay. Table 2 shows results obtained for 4
representative samples covering the measuring range of the 20 tested.
Repeatability of sample preparation for toxin detection. To evaluate the repeat-
ability of the sample preparation method for toxin detection, clinical specimens from
different consistencies, ranging from liquid to formed stools, were used. A good
repeatability of toxin quantiﬁcation was observed for all six liquid samples tested
(Bristol stool chart type 7). Table 3 shows the results obtained for toxin A (CVs below
10% for the eight independent preparations of each sample). For semiformed (Bristol
stool chart types 5 and 6) and formed samples (Bristol stool chart types 1 to 4), four of
the six samples tested had a CV of less than 10%. The two formed samples with CVs
greater than 10% were classiﬁed as hard stool using the Bristol stool chart (type 1 and
2), while the two semiformed samples had a consistency that was difﬁcult to homog-
enize. The issue of obtained repeatability with these samples was directly correlated to
the stool consistency (hard stool or ﬁbrous/ﬁlamentous samples) and the difﬁculty of
efﬁciently homogenizing the sample in the diluent.
Sensitivity and speciﬁcity of SIMOA toxin assays. The sensitivity and speciﬁcity of
SIMOA toxin assays were evaluated with clinical samples from 240 patients, consisting
of 126 females and 114 males of ages ranging from 7 to 86 years, with a median of 74
years. Using a laboratory case deﬁnition, 66 patients were diagnosed with CDI while 174
patients were CDI negative.
Figure 2 shows the ROC curves of the toxin concentration relative to the CDI status
of the patients. The areas under the curve (AUC) obtained for SIMOA toxin A and toxin
B assays were 0.941 and 0.969, respectively. The selected clinical thresholds were 22.1
and 18.8 pg/ml for toxin A and toxin B, respectively, giving sensitivities of 84.8 and
95.5% and speciﬁcities of 83.9 and 83.3% compared to the laboratory case deﬁnition
(Table 4). By comparison, the C. difﬁcile Tox A/B II showed a lower sensitivity of 71.2%
and a higher speciﬁcity of 95.4% compared to the laboratory case deﬁnition. The
sensitivity and speciﬁcity of the combined SIMOA toxin assays were determined by
considering a sample positive if at least one of the two assays gave a positive result.
Accordingly, the sensitivity of combined SIMOA assays corresponds to the sensitivity of
the toxin B assay, which has the higher sensitivity of the two. The speciﬁcity of the
combined assays is lower than the speciﬁcity of each assay due to the fact that 8
samples were positive for toxin B only and 7 for toxin A only (Fig. 3).
FIG 1 Assay measuring range; calibration curves of SIMOA toxin A and toxin B assays. The graphs represent the mean of average enzyme
per bead (AEB) values, corresponding to SIMOA signal output, obtained with SIMOA toxin A and toxin B assays for eight calibrators
(puriﬁed native toxins), which ranged from 0 to 2000 pg/ml. Means and standard deviations for each calibrator correspond to duplicates
of eight individual runs on an SIMOA HD-1 analyzer. Regression equations and coefﬁcients of determination (R2) of the slopes are indicated
on each ﬁgure.
TABLE 1 LOB, LOD, and LOQ of both SIMOA toxin assays in pretreated samplesa
Test LOB (pg/ml) LOD (pg/ml) LOQ (pg/ml)
SIMOA toxin A 0.4 0.6 1.7
SIMOA toxin B 2.4 2.9 2.9
aLOB, limit of blank; LOD, limit of detection; LOQ, limit of quantiﬁcation.
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The low speciﬁcity of both SIMOA assays in comparison to the laboratory case
deﬁnition is mainly due to the 29 SIMOA toxin-positive results among the 46 GDH- and
PCR-positive and CCNA-negative samples (Fig. 3). Some of those samples (n  8/29;
28%) were also positive by the C. difﬁcile Tox A/B II assay. These SIMOA toxin-positive
samples were retested inhouse with bMx CCNA and 86% (25/29, Fig. 3) were found
positive at a low dilution factor. Discrepancy in the CCNA results between the Leeds
laboratory and the bioMérieux inhouse results may be explained by several facts,
including the different methods used (cells, antibodies, sample dilution, and neutral-
izing antibody) and the visual analysis of cytotoxicity. Nevertheless, analysis of discor-
dant results with bMx CCNA showed 11 SIMOA false-positive (toxin A and/or B) results
(Fig. 3).
The sensitivity of the SIMOA toxin B assay was higher than the sensitivity of the toxin
A assay, as expected, given that the comparison was done with CCNA, an assay more
sensitive to toxin B (Table 4). Toxin A was not detected in 10 CCNA-positive samples,
while toxin B was not detected in only 3 of these 10 samples (Fig. 3 and 4). Repeat
inhouse bMx CCNA for these 3 samples gave a negative result for 2 of them, suggesting
a potential degradation of the toxins. By comparison, the C. difﬁcile Tox A/B II assay was
negative in 19 of the 66 CCNA-positive samples. The SIMOA toxin B assay detected
toxins in 84% (16/19) of EIA-negative samples, resulting in 24% (16/66) more samples
determined as positive (Fig. 3 and 4).
For a third of the samples, an additional freezing/thawing cycle occurred before
testing with the C. difﬁcile Tox A/B II assay. Thirteen of the 19 CCNA-positive samples,
which got an additional freezing/thawing cycle, gave a positive result with the C.
difﬁcile Tox A/B II assay, and 6 were found negative, one also being negative with
SIMOA. Among the 56 negative samples having an additional freezing/thawing cycle,
four gave a positive result with C. difﬁcile Tox A/B II assay. These samples were also
found positive with the Xpert C. difﬁcile assay and inhouse bMx CCNA. The sensitivity
and speciﬁcity calculated on the 165 samples that did not get an additional freezing/
thawing cycle, gave equivalent results to the sensitivity and speciﬁcity determined on
all the samples (Table 5).
DISCUSSION
EIAs detecting toxins have been developed to facilitate diagnosis of CDI, but none
of the commercially available EIAs has sensitivity equivalent to that of CCNA (13). On
the other hand, molecular assays detecting C. difﬁcile genes (including toxin genes)
have shown higher sensitivity in comparison that of to CCNA but have been criticized
for detecting colonized patients having diarrhea for other reasons (15). Furthermore,
TABLE 2 Repeatability and reproducibility of SIMOA toxin assays
Sample
Assay for toxin A Assay for toxin B
Mean toxin (pg/ml) Intra-assay CVa (%) Interassay CV (%) Mean toxin (pg/ml) Intra-assay CV (%) Interassay CV (%)
1 3.7 4.9 5.4 3.2 7.1 9.8
2 12 3.4 4.9 10.4 3.6 11.3
3 32 2.2 3.8 28 4 7.4
4 633 3.6 5.8 687 0 7.8
TABLE 3 Repeatability of sample preparation for toxin A detection
Sample
Liquid samples Semiformed samples Formed samples
Toxin A (pg/ml) CV (%) Toxin A (pg/ml) CV (%) Toxin A (pg/ml) CV (%)
1 74 2.4 70 7.2 33 8
2 176 6.4 154 2.1 62 11.6
3 198 4.5 171 7.1 134 5
4 450 2.1 450 18.4 737 5.4
5 1,020 7.2 459 38.4 1,413 19.7
6 2,365 4.7 692 6.4 2,788 2.5
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work done by Polage et al. and Planche et al. have shown that patients outcome differs
according to the testing method. The presence of toxin in the stool strongly correlates
with duration of the symptoms and with disease severity, whereas the presence of toxin
gene alone did not (12, 22). These results suggest that a sensitive automated assay for
the detection and quantiﬁcation of C. difﬁcile toxins in stool could be the most
appropriate method for CDI diagnosis. Assays detecting toxins A and B have been
recently developed using the SIMOA technology and showed a sensitivity of toxin B
assay equivalent to that of CCNA and a speciﬁcity close to that of molecular assays and
toxigenic culture (20).
We have developed SIMOA toxin A and toxin B assays according to Quanterix
methods, using raw materials similar to the ones described by Song et al. (21), and
showed that these assays have a better analytical performance than one of the best
EIAs commercially available. Our SIMOA toxin A and toxin B assays have LOD of 0.6 and
2.9 pg/ml in pretreated fecal aliquots, respectively, corresponding to 0.013 and 0.061
pg/mg of toxin in original stool samples. These results are slightly different from the
ones previously described (LOD, 0.45 and 1.5 pg/ml, corrected for the dilution factor)
(21). We believe that this is probably related to the native toxins, which are used as
calibrators, and the method used to deﬁne these values. Nevertheless, with our clinical
cutoffs of 22.1 and 18.8 pg/ml for toxin A and toxin B assays in pretreated samples, we
observed similar sensitivity and speciﬁcity to the ones published in Song et al. (21),
even though the patient populations were not characterized in the same way. In our
study, the sensitivity of the SIMOA toxin B assay in comparison to the laboratory case
deﬁnition was 95.5%, while the sensitivity described by Song et al. (21) was 100% in
comparison to that of CCNA. The speciﬁcities of our SIMOA toxin A and toxin B assays,
compared to that of the Leeds CCNA, were 83.9% and 83.3%, respectively, while Song
et al.’s results were 84% and 87%. In both our and Song et al.’s studies, a number of
PCR-positive CCNA-negative samples were found positive by the SIMOA toxin assays.
Some of the samples also gave a positive result by the C. difﬁcile Tox A/B II assay. As
previously mentioned by Song et al. (21), this not only brings into question the
sensitivity of CCNA, but also the accuracy, reproducibility, and robustness of this poorly
FIG 2 Receiver operating characteristic (ROC) curves obtained for SIMOA toxin A (A) and toxin B (B)
assays. The ROC curves of SIMOA toxin A and toxin B assays are created by plotting the true-positive rate
against the false-positive rate at various threshold settings, using the concentration obtained for each
pretreated sample and the CDI status of the patient (n  240).
TABLE 4 Sensitivity and speciﬁcity of SIMOA toxin assays compared to CDI statusa
Test
Sensitivity (% [95% CI])
(n  66)
Speciﬁcity (% [95% CI])
(n  174)
SIMOA toxin A 84.8 (73.9–92.5) 83.9 (77.6–89)
SIMOA toxin B 95.5 (87.3–99.1) 83.3 (77–88.6)
SIMOA toxin A  B 95.5 (87.3–99.1) 79.3 (72.5–85.1)
C. difﬁcile Tox A/B II 71.2 (58.8–81.7) 95.4 (91.1–98)
aTotals of 66 GDH- and CCNA-positive samples and 174 GDH- and/or CCNA-negative samples. CI, conﬁdence
interval.
Banz et al. Journal of Clinical Microbiology
August 2018 Volume 56 Issue 8 e00452-18 jcm.asm.org 6
 o
n
 January 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
standardized assay, which can be performed on different cell lines, using various
dilutions, and sometimes without antitoxin conﬁrmation. The quantity of toxin mea-
sured by SIMOA assay in these samples was low in comparison to the quantity in other
CDI patients, also observed by Song et al. The methodology of EIAs and CCNAs are not
FIG 3 Number of samples given a positive result with SIMOA assays and the C. difﬁcile TOX A/B II, according
to Leeds laboratory results. The ﬁgure shows the number of patients tested and the number of positive and
negative results obtained with GDH screen, Leeds CCNA, and PCR assay. For each group, the number of
samples positive by SIMOA toxin A assay, SIMOA toxin B assay or both SIMOA assays and with C. difﬁcile TOX
A/B II are indicated. The results obtained with bioMérieux’s CCNA (bMx CCNA) for discordant results are also
indicated, as well as the number of samples which got an additional freezing cycle.
FIG 4 SIMOA toxin A and toxin B assay results according to laboratory case deﬁnition of CDI and
comparison to C. difﬁcile TOX A/B II assay results. Toxin A and toxin B concentrations measured with
SIMOA assays in each diluted sample (n  240) are plotted according to the CDI status of the patient,
CDI diagnosed (GDH- and Leeds CCNA-positive sample) or CDI not diagnosed (GDH- and/or Leeds
CCNA-negative sample). The positivity thresholds of SIMOA toxin A and toxin B assays are indicated by
a line on each ﬁgure (toxin A, 22.1 pg/ml; toxin B, 18.8 pg/ml). Each circle corresponds to a quantity of
toxin determined by SIMOA assays, and dark circles represents the sample which are positive by the C.
difﬁcile TOX A/B II assay. Toxin concentrations in the graph are not corrected by the dilution factor.
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the same. Detection of C. difﬁcile toxin B presence is physically determined by EIA,
whereas CCNA results demonstrate the results of toxin B activity. One potential
explanation for the SIMOA-positive CCNA-negative samples may be the preanalytical
loss of toxin B activity, whereas toxins remain detectable by immunoassay.
At this time, we do not understand the true meaning for patients when a low toxin
concentration is detected. Highly sensitive toxin assays may suffer from the same
speciﬁcity problem as highly sensitive molecular tests, which can lead to the erroneous
identiﬁcation of uninfected individuals as CDI patients (23). Since it is considered
unnecessary to treat colonized patients (24), we face a clinical quandary about how to
manage individuals with low fecal toxin concentrations—are they colonized or in-
fected? Whether we can distinguish infected and colonized patients with SIMOA C.
difﬁcile toxin assays, based on toxin concentrations, is currently unknown. Additional
epidemiologic and interventional studies are required to answer this question.
The limits of our study are the lack of clinical conﬁrmation of CDI status, the number
of samples tested, the comparison to other EIAs detecting toxins, and the fact that an
additional freezing/thawing cycle occurred for some samples prior to testing with the
C. difﬁcile Tox A/B II assay. It is known that a freezing/thawing cycle is not recom-
mended for toxin stability. Nevertheless, it is important to point out that toxins were
detected by C. difﬁcile Tox A/B II assay in samples that had an additional freezing/
thawing cycle, and that the sensitivity and speciﬁcity values were not different without
these samples. Finally, clinical correlation studies of CDI presentation and outcome with
a large number of samples will be required for determination of the diagnostic accuracy
of these assays.
In our comparison of the SIMOA assays and the C. difﬁcile Tox A/B II assay, we
observed that the SIMOA toxin A and toxin B assays have higher sensitivities than the
C. difﬁcile Tox A/B II assay (84.8 and 95.5% versus 71.2%). The use of the SIMOA assays
allowed the detection of toxin-positive samples that would have been missed by the
commercial EIA. In comparison to the analytical sensitivity of EIAs determined in diluted
supernatant (without correction by dilution factor), we described a LOD of toxin B of 2.9
pg/ml, corresponding to 0.061 pg/mg of toxin in the stool. Hence, C. difﬁcile toxin
detection using SIMOA technology has the potential to improve CDI diagnosis. The
SIMOA assay could replace current EIAs for laboratories that do not have the skills and
capacity to perform CCNA and would increase the speciﬁcity of positive results com-
pared with that of current molecular tests.
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TABLE 5 Sensitivity and speciﬁcity of SIMOA toxin assays compared to CDI status using
samples that did not get an additional freezing/thawing cyclea
Test
Sensitivity (% [95% CI])
(n  47)
Speciﬁcity (% [95% CI])
(n  118)
SIMOA toxin A 85.1 (71.7–93.8) 85.6 (77.9–91.4)
SIMOA toxin B 95.7 (85.5–99.5) 85.6 (77.9–91.4)
SIMOA toxin A  B 95.7 (85.5–99.5) 80.5 (72.2–87.2)
C. difﬁcile Tox A/B II 72.3 (57.4–84.4) 96.6 (91.5–99.1)
aTotals of 47 GDH- and CCNA-positive samples and 118 GDH- and/or CCNA-negative samples.
Banz et al. Journal of Clinical Microbiology
August 2018 Volume 56 Issue 8 e00452-18 jcm.asm.org 8
 o
n
 January 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
REFERENCES
1. Bartlett JG. 1994. Clostridium difﬁcile: history of its role as an enteric
pathogen and the current state of knowledge about the organism.
Clin Infect Dis 18(Suppl 4):S265–S272. https://doi.org/10.1093/clinids/
18.Supplement_4.S265.
2. Kwon JH, Olsen MA, Dubberke ER. 2015. The morbidity, mortality, and
costs associated with Clostridium difﬁcile infection. Infect Dis Clin North
Am 29:123–134. https://doi.org/10.1016/j.idc.2014.11.003.
3. Cloud J, Noddin L, Pressman A, Hu M, Kelly C. 2009. Clostridium difﬁcile
strain NAP-1 is not associated with severe disease in a nonepidemic
setting. Clin Gastroenterol Hepatol 7:868–873. https://doi.org/10.1016/
j.cgh.2009.05.018.
4. Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, van den Berg RJ,
Kuijper EJ. 2009. Successful combat of an outbreak due to Clostridium
difﬁcile PCR ribotype 027 and recognition of speciﬁc risk factors. Clin Micro-
biol Infect 15:427–434. https://doi.org/10.1111/j.1469-0691.2009.02713.x.
5. Vaishnavi C. 2009. Established and potential risk factors for Clostridum
difﬁcile infection. Indian J Med Microbiol 27:289–300. https://doi.org/10
.4103/0255-0857.55436.
6. Khanafer N, Vanhems P, Barbut F, Luxemburger C. 2017. Factors associ-
ated with Clostridium difﬁcile infection: a nested case-control study in a
three year prospective cohort. Anaerobe 44:117–123. https://doi.org/10
.1016/j.anaerobe.2017.03.003.
7. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan
PH, McFarland LV, Mellow M, Zuckerbraun BS. 2013. Guidelines for diagno-
sis, treatment, and prevention of Clostridium difﬁcile infections. Am J Gas-
troenterol 108:478–498. https://doi.org/10.1038/ajg.2013.4.
8. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Cofﬁn SE,
Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee SJ, Sandora TJ,
Wilcox MH. 2018. Clinical practice guidelines for Clostridium difﬁcile
infection in adults and children: 2017 update by the Infectious Diseases
Society of America (IDSA) and Society for Healthcare Epidemiology of
America (SHEA). Clin Infect Dis 66:e1-e48. https://doi.org/10.1093/cid/
cix1085.
9. Debast SB, Bauer MP, Kuijper EJ. 2014. European Society of Clinical
Microbiology and Infectious Diseases: update of the treatment guidance
document for Clostridium difﬁcile infection. Clin Microbiol Infect
20(Suppl 2):S1–S26. https://doi.org/10.1111/1469-0691.12418.
10. Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM,
Wilcox MH, Kuijper EJ. 2016. European Society of Clinical Microbiology
and Infectious Diseases: update of the diagnostic guidance document
for Clostridium difﬁcile infection. Clin Microbiol Infect 22(Suppl 4):
S63–S81. https://doi.org/10.1016/j.cmi.2016.03.010.
11. Barbut F, Petit JC. 2001. Epidemiology of Clostridium difﬁcile-associated
infections. Clin Microbiol Infect 7:405–410. https://doi.org/10.1046/j
.1198-743x.2001.00289.x.
12. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA,
O’Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox
MH. 2013. Differences in outcome according to Clostridium difﬁcile test-
ing method: a prospective multicentre diagnostic validation study of C
difﬁcile infection. Lancet Infect Dis 13:936–945. https://doi.org/10.1016/
S1473-3099(13)70200-7.
13. Eastwood K, Else P, Charlett A, Wilcox M. 2009. Comparison of nine
commercially available Clostridium difﬁcile toxin detection assays, a real-
time PCR assay for C. difﬁcile tcdB, and a glutamate dehydrogenase
detection assay to cytotoxin testing and cytotoxigenic culture methods.
J Clin Microbiol 47:3211–3217. https://doi.org/10.1128/JCM.01082-09.
14. Rene P, Frenette CP, Schiller I, Dendukuri N, Brassard P, Fenn S, Loo VG.
2012. Comparison of eight commercial enzyme immunoassays for the
detection of Clostridium difﬁcile from stool samples and effect of strain
type. Diagn Microbiol Infect Dis 73:94–96. https://doi.org/10.1016/j
.diagmicrobio.2012.01.005.
15. Eckert C, Jones G, Barbut F. 2013. Diagnosis of Clostridium difﬁcile infection:
the molecular approach. Future Microbiol 8:1587–1598. https://doi.org/10
.2217/fmb.13.129.
16. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. 1989. Nosocomial
acquisition of Clostridium difﬁcile infection. N Engl J Med 320:204–210.
https://doi.org/10.1056/NEJM198901263200402.
17. Furuya-Kanamori L, Clements AC, Foster NF, Huber CA, Hong S, Harris-
Brown T, Yakob L, Paterson DL, Riley TV. 2016. Asymptomatic Clostridium
difﬁcile colonisation in two Australian tertiary hospitals, 2012–2014: a
prospective, repeated cross-sectional study. Clin Microbiol Infect 23:
48.e1-48.e7. https://doi.org/10.1016/j.cmi.2016.08.030.
18. Rissin DM, Fournier DR, Piech T, Kan CW, Campbell TG, Song L, Chang L,
Rivnak AJ, Patel PP, Provuncher GK, Ferrell EP, Howes SC, Pink BA,
Minnehan KA, Wilson DH, Duffy DC. 2011. Simultaneous detection of
single molecules and singulated ensembles of molecules enables im-
munoassays with broad dynamic range. Anal Chem 83:2279–2285.
https://doi.org/10.1021/ac103161b.
19. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, Meyer
RE, Fishburn MW, Cabrera C, Patel PP, Frew E, Chen Y, Chang L, Ferrell EP,
von EV, McGuigan W, Reinhardt M, Sayer H, Vielsack C, Duffy DC. 2016.
The Simoa HD-1 analyzer: a novel fully automated digital immunoassay
analyzer with single-molecule sensitivity and multiplexing. J Lab Autom
21:533–547. https://doi.org/10.1177/2211068215589580.
20. Pollock NR, Song L, Zhao M, Duffy DC, Chen X, Sambol SP, Gerding DN,
Kelly CP. 2015. Differential immunodetection of toxin B from highly
virulent Clostridium difﬁcile BI/NAP-1/027. J Clin Microbiol 53:1705–1708.
https://doi.org/10.1128/JCM.03419-14.
21. Song L, Zhao M, Duffy DC, Hansen J, Shields K, Wungjiranirun M, Chen
X, Xu H, Lefﬂer DA, Sambol SP, Gerding DN, Kelly CP, Pollock NR. 2015.
Development and validation of digital enzyme-linked immunosorbent
assays for ultrasensitive detection and quantiﬁcation of Clostridium dif-
ﬁcile toxins in stool. J Clin Microbiol 53:3204–3212. https://doi.org/10
.1128/JCM.01334-15.
22. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen
HH, Huang B, Tang YW, Lee LW, Kim K, Taylor S, Romano PS, Panacek EA,
Goodell PB, Solnick JV, Cohen SH. 2015. Overdiagnosis of Clostridium
difﬁcile infection in the molecular test era. JAMA Intern Med 175:
1792–1801. https://doi.org/10.1001/jamainternmed.2015.4114.
23. Dubberke ER, Burnham CA. 2015. Diagnosis of Clostridium difﬁcile
infection: treat the patient, not the test. JAMA Intern Med 175:
1801–1802. https://doi.org/10.1001/jamainternmed.2015.4607.
24. Planche T, Wilcox MH. 2015. Diagnostic pitfalls in Clostridium difﬁcile
infection. Infect Dis Clin North Am 29:63–82. https://doi.org/10.1016/j
.idc.2014.11.008.
Ultrasensitivity Assays for C. difﬁcile Toxins Journal of Clinical Microbiology
August 2018 Volume 56 Issue 8 e00452-18 jcm.asm.org 9
 o
n
 January 8, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
